Literature DB >> 23606404

Predictive value of human papillomavirus in oropharyngeal carcinoma treated with radiotherapy: An updated systematic review and meta-analysis of 30 trials.

Fausto Petrelli1, Enrico Sarti, Sandro Barni.   

Abstract

BACKGROUND: Human papillomavirus-positive (HPV+) oropharyngeal squamous cell carcinoma (OSCC) is emerging as a different subtype of head and neck cancer. The authors conducted a systematic review and meta-analysis to examine the predictive role of HPV in patients with OSCC treated with radiotherapy-based modality therapy.
METHODS: The authors performed a PubMed search to identify published trials that evaluated the outcome of HPV+ OSCC treated with radiotherapy. Hazard ratios (HRs) were extracted and pooled by using random or fixed effects models. The primary endpoints were overall survival (OS), disease-specific survival, (DSS), and disease-free survival (DFS).
RESULTS: Thirty trials were available for HPV analysis. HPV+ status is associated with better OS (HR = 0.33; p < .00001), DSS (HR = 0.24; p < .00001), and DFS (HR = 0.31; p < .00001).
CONCLUSION: HPV+ OSCC has a better survival compared to HPV-negative disease when treated with radiotherapy-based modality therapy.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  human papillomavirus; oropharyngeal carcinoma; predictive factor; radiotherapy; survival

Mesh:

Year:  2013        PMID: 23606404     DOI: 10.1002/hed.23351

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  16 in total

1.  Validation of an updated evidence-based protocol for proactive gastrostomy tube insertion in patients with head and neck cancer.

Authors:  T E Brown; V Getliffe; M D Banks; B G M Hughes; C Y Lin; L M Kenny; J D Bauer
Journal:  Eur J Clin Nutr       Date:  2016-02-10       Impact factor: 4.016

2.  Human papillomavirus in oropharyngeal cancer in Canada: analysis of 5 comprehensive cancer centres using multiple imputation.

Authors:  Steven Habbous; Karen P Chu; Harold Lau; Melissa Schorr; Mathieos Belayneh; Michael N Ha; Scott Murray; Brian O'Sullivan; Shao Hui Huang; Stephanie Snow; Matthew Parliament; Desiree Hao; Winson Y Cheung; Wei Xu; Geoffrey Liu
Journal:  CMAJ       Date:  2017-08-14       Impact factor: 8.262

3.  Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.

Authors:  Natalie M Lowe; Jonathan M Bernstein; Kathleen Mais; Kate Garcez; Lip W Lee; Andrew Sykes; David J Thomson; Jarrod J Homer; Catharine M West; Nicholas J Slevin
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-08       Impact factor: 4.553

4.  Diffuse optical measurements of head and neck tumor hemodynamics for early prediction of chemoradiation therapy outcomes.

Authors:  Lixin Dong; Mahesh Kudrimoti; Daniel Irwin; Li Chen; Sameera Kumar; Yu Shang; Chong Huang; Ellis L Johnson; Scott D Stevens; Brent J Shelton; Guoqiang Yu
Journal:  J Biomed Opt       Date:  2016-08-01       Impact factor: 3.170

Review 5.  Modulation of therapeutic sensitivity by human papillomavirus.

Authors:  Adam D Swick; Anirban Chatterjee; Anna-Maria A De Costa; Randall J Kimple
Journal:  Radiother Oncol       Date:  2015-09-10       Impact factor: 6.280

6.  A proportion of primary squamous cell carcinomas of the parotid gland harbour high-risk human papillomavirus.

Authors:  Bin Xu; Lu Wang; Laetitia Borsu; Ronald Ghossein; Nora Katabi; Ian Ganly; Snjezana Dogan
Journal:  Histopathology       Date:  2016-08-23       Impact factor: 5.087

7.  ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines.

Authors:  Anil Prasad; Nagina Khudaynazar; Ramana V Tantravahi; Amanda M Gillum; Benjamin S Hoffman
Journal:  Oncotarget       Date:  2016-11-29

Review 8.  Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers.

Authors:  V Bol; V Grégoire
Journal:  Biomed Res Int       Date:  2014-04-03       Impact factor: 3.411

9.  The rationale for HPV-related oropharyngeal cancer de-escalation treatment strategies.

Authors:  Małgorzata Wierzbicka; Krzysztof Szyfter; Piotr Milecki; Krzysztof Składowski; Rodryg Ramlau
Journal:  Contemp Oncol (Pozn)       Date:  2015-09-28

10.  Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.

Authors:  Chia-Jung Busch; Benjamin Becker; Malte Kriegs; Fruzsina Gatzemeier; Katharina Krüger; Nikolaus Möckelmann; Gerhard Fritz; Cordula Petersen; Rainald Knecht; Kai Rothkamm; Thorsten Rieckmann
Journal:  Oncotarget       Date:  2016-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.